BJDX:NSD-Bluejay Diagnostics Inc. Common Stock (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 2.66

Change

0.00 (0.00)%

Market Cap

USD 0.05B

Volume

0.59M

Avg Analyst Target

USD 10.00 (+275.94%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Bluejay Diagnostics Inc. Common Stock (BJDX) Stock Analysis:
Based on the Bluejay Diagnostics Inc. Common Stock stock forecasts from 1 analysts, the average analyst target price for Bluejay Diagnostics Inc. Common Stock is USD 10.00 over the next 12 months. Bluejay Diagnostics Inc. Common Stock’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Bluejay Diagnostics Inc. Common Stock is Slightly Bearish, which is based on 1 positive signals and 2 negative signals. At the last closing, Bluejay Diagnostics Inc. Common Stock’s stock price was USD 2.66. Bluejay Diagnostics Inc. Common Stock’s stock price has changed by -0.13% over the past week, -0.12% over the past month and +0.00% over the last year.

About

Bluejay Diagnostics, Inc., an in-vitro diagnostic company, develops, manufactures, and markets minimally invasive point-of-care (POC) diagnostics tests and devices for infectious disease, inflammation, and oncology markets in the United States. It is developing Symphony biomarker ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-17 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
DXCM DexCom Inc

N/A

USD43.36B 84.37 117.62
ALGN Align Technology Inc

N/A

USD41.37B 56.55 48.05
PODD Insulet Corporation

N/A

USD16.74B 2,208.27 199.97
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
ABMD Abiomed Inc

N/A

USD13.70B 92.48 46.15
BRKR Bruker Corporation

N/A

USD10.73B 39.93 25.78
TNDM Tandem Diabetes Care Inc

N/A

USD7.67B 356.22 187.52
SWAV ShockWave Medical Inc

N/A

USD5.90B N/A N/A
IART Integra LifeSciences Holdings ..

N/A

USD5.83B 27.08 17.89
LIVN LivaNova PLC

N/A

USD4.51B 77.40 N/A

ETFs Containing BJDX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.91% 85% B 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.91% 85% B 85% B
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.05B 22% F 13% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -101.97 94% A 92% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 47.73% 92% A- 96% A
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.15 98% A+ 94% A
Short Percent 4.70% 40% F 34% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.